menu
    • menu
    [{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"PMC-309","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ PharmAbcine","highestDevelopmentStatusID":"4","companyTruncated":"Thermo Fisher Scientific \/ PharmAbcine"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fisher Scientific \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"FLT180a","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Freeline Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Thermo Fisher Scientific \/ Freeline Therapeutics"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thermo Fisher Scientific \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Humanigen"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Relmacabtagene autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ JW Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ JW Therapeutics"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Thermo Fisher Scientific \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fisher Scientific \/ Moderna"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Thermo Fisher Scientific \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fisher Scientific \/ Merck"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Thermo Fisher Scientific \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fisher Scientific \/ Moderna"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Eblasakimab","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Thermo Fisher Scientific \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"GLPG-5101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ Galapagos"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Bayer AG"}]

    Find Clinical Drug Pipeline Developments & Deals by Thermo Fisher Scientific

    Menu

    Thermo Fisher Scientific

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darolutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bayer and Thermo Fisher Collaborate To Enhance Access To Cancer Medicines

                            Details : The collaboration aims to develop sequencing-based companion diagnostics to identify patients who may benefit from Bayer’s precision cancer therapies, including Nubeqa for prostate cancer.

                            Brand Name : Nubeqa

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : Darolutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLPG-5101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Galapagos Partners with Thermo Fisher To Expand CAR-T Manufacturing Network in the U.S.

                            Details : Thermo Fisher will provide GMP manufacturing, BioServices, and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program, GLPG-5101, developed for Non-Hodgkin’s lymphoma treatment.

                            Brand Name : GLPG-5101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : GLPG-5101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Galapagos

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eblasakimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : ASLAN Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Form...

                            Details : ASLAN004 (eblasakimab) is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).

                            Brand Name : ASLAN004

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : Eblasakimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : ASLAN Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elasomeran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

                            Details : As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling for Spikevax. In addition, the company will provide inspection, labeling and final ...

                            Brand Name : Spikevax

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 23, 2022

                            Lead Product(s) : Elasomeran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine...

                            Details : This agreement is part of Merck’s commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies. Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics.

                            Brand Name : MK-4482

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2021

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-1273

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-1...

                            Details : Thermo Fisher’s commercial manufacturing site in Greenville, North Carolina will be used for aseptic fill/finish, labeling and packaging to support the production of millions of doses of mRNA-1273. Production will begin in the third quarter of 2021.

                            Brand Name : Spikevax

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 01, 2021

                            Lead Product(s) : mRNA-1273

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relmacabtagene autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : JW Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China

                            Details : The Partnership will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics’ lead product relmacabtagene autoleucel (“relma-cel”).

                            Brand Name : Relma-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 03, 2021

                            Lead Product(s) : Relmacabtagene autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : JW Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FLT180a

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Spur Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Freeline Announces Supply Agreement for Haemophilia B Program With Thermo Fisher Scientific

                            Details : Freeline has established the manufacturing process for FLT180a at Thermo Fisher’s Cambridge facility over the past two years, most recently initiating clinical supply production there for its planned Phase 2b/3 pivotal clinical trial of FLT180a.

                            Brand Name : FLT180a

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : FLT180a

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Spur Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzi...

                            Details : The partnership adds to Humanigen’s large scale commercial production efforts, including collaborations with Lonza and Catalent, for a potential 2020 EUA and subsequent commercialization of lenzilumab.

                            Brand Name : Humaneered

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Thermo Fisher Scientific

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entrectinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Thermo Fisher Signs CDx Agreement with Chugai Pharma

                            Details : Approval by the MHLW would accelerate access to Chugai's targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.

                            Brand Name : Rozlytrek

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 08, 2020

                            Lead Product(s) : Entrectinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth